{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT03174977",
            "orgStudyIdInfo": {
                "id": "15-17586"
            },
            "organization": {
                "fullName": "University of California, San Francisco",
                "class": "OTHER"
            },
            "briefTitle": "Pharmacokinetics Distribution of Raltegravir by PET/MR",
            "officialTitle": "Pharmacokinetics Distribution of Raltegravir Using Radiolabeling in HIV-infected Patients by PET/MR: a Pilot Study.",
            "therapeuticArea": [
                "Infectious Diseases"
            ],
            "study": "pharmacokinetics-distribution-of-raltegravir-by-pet-mr"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-06",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2018-04-01",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-11-01",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-01-01",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2017-03-03",
            "studyFirstSubmitQcDate": "2017-05-31",
            "studyFirstPostDateStruct": {
                "date": "2017-06-05",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-06-14",
            "lastUpdatePostDateStruct": {
                "date": "2024-06-18",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "University of California, San Francisco",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "Merck Sharp & Dohme LLC",
                    "class": "INDUSTRY"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false,
            "isUsExport": false
        },
        "descriptionModule": {
            "briefSummary": "This is a single-center drug distribution and pharmacokinetic study of a single microdose of 18F-raltegravir given to 10 HIV-infected subjects who are either taking or not taking a raltegravir-containing ART regimen. After administration of IV 18F-raltegravir, subjects will undergo PET/MRI in order to determine the distribution of radiolabeled drug through the lymphoreticular system and other tissues throughout the entire body."
        },
        "conditionsModule": {
            "conditions": [
                "HIV-1-infection"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "EARLY_PHASE1"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "primaryPurpose": "OTHER",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 10,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "18F-Raltegravir",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: 18F-Raltegravir"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "18F-Raltegravir",
                    "description": "A single microdose of 18F-Raltegravir will be given to individuals currently being treated for HIV-1 with antiretroviral therapy.",
                    "armGroupLabels": [
                        "18F-Raltegravir"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Number of patients with microdose (<2.5 millicurie; mCi) 18F-Raltegravir-related adverse events as measured by clinical observation during single intravenous dose administration and PET/MR imaging",
                    "timeFrame": "One imaging session within 1 to 6 hours following administration of 18F-Raltegravir"
                },
                {
                    "measure": "Whole-body distribution (coronal through pelvis) of radiolabeled 18F-Raltegravir as determined by PET-MR scanning and quantification of radiographic regions of interest (ROI) immediately following and up to 4 hours after drug administration.",
                    "timeFrame": "One imaging session within 1 to 6 hours following administration of 18F-Raltegravir"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Age \u226518 years\n* HIV infection\n* Initiated a combination ART (HAART) regimen\n\nExclusion Criteria:\n\n* Screening absolute neutrophil count \\<1,000 cells/mm3, platelet count \\<70,000 cells/mm3, hemoglobin \\< 8 mg/dL, estimated creatinine clearance \\<40 mL/minute, aspartate aminotransferase \\>100 units/L, alanine aminotransferase \\>100 units/L.\n* Serious illness requiring hospitalization or parental antibiotics within the preceding 3 months.\n* Any vaccination 2 weeks prior to baseline (Day 0) visit and throughout the study period.\n* Concurrent treatment with immunomodulatory drugs, or exposure to any immunomodulatory drug in the preceding 16 weeks (e.g. corticosteroid therapy equal to or exceeding a dose of 15 mg/day of prednisone for more than 10 days, IL-2, interferon-alpha, methotrexate, cancer chemotherapy). NOTE: Use of inhaled or nasal steroid use is not exclusionary.\n* Pregnant or breastfeeding women. Females of childbearing potential must have a negative serum pregnancy test at screening and agree to use a double-barrier method of contraception throughout the study period.\n* Have a cardiac pacemaker or other indwelling foreign object that are contraindicated for MR imaging.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Timothy J Henrich, MD",
                    "role": "CONTACT",
                    "phone": "415-206-5518",
                    "email": "timothy.henrich@ucsf.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Timothy J Henrich, MD",
                    "affiliation": "University of California, San Francisco",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "University of California, San Francisco",
                    "status": "RECRUITING",
                    "city": "San Francisco",
                    "state": "California",
                    "zip": "94110",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Timothy J Henrich, MD",
                            "role": "CONTACT",
                            "phone": "415-206-5518",
                            "email": "timothy.henrich@ucsf.edu"
                        },
                        {
                            "name": "Timothy J Henrich, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        },
                        {
                            "name": "Henry F Vanbrocklin, PhD",
                            "role": "SUB_INVESTIGATOR"
                        },
                        {
                            "name": "Steven J Deeks, MD",
                            "role": "SUB_INVESTIGATOR"
                        },
                        {
                            "name": "Benajamin Franc, MD",
                            "role": "SUB_INVESTIGATOR"
                        },
                        {
                            "name": "Francesca Aweeka, PharmD",
                            "role": "SUB_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 37.77493,
                        "lon": -122.41942
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M3522",
                    "name": "Acquired Immunodeficiency Syndrome",
                    "relevance": "LOW"
                },
                {
                    "id": "M18250",
                    "name": "HIV Infections",
                    "relevance": "LOW"
                },
                {
                    "id": "M10283",
                    "name": "Infections",
                    "relevance": "LOW"
                },
                {
                    "id": "M6368",
                    "name": "Communicable Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC01",
                    "name": "Infections"
                },
                {
                    "abbrev": "BXS",
                    "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
                },
                {
                    "abbrev": "BC20",
                    "name": "Immune System Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000068898",
                    "term": "Raltegravir Potassium"
                }
            ],
            "ancestors": [
                {
                    "id": "D000019380",
                    "term": "Anti-HIV Agents"
                },
                {
                    "id": "D000044966",
                    "term": "Anti-Retroviral Agents"
                },
                {
                    "id": "D000000998",
                    "term": "Antiviral Agents"
                },
                {
                    "id": "D000000890",
                    "term": "Anti-Infective Agents"
                },
                {
                    "id": "D000019428",
                    "term": "HIV Integrase Inhibitors"
                },
                {
                    "id": "D000019429",
                    "term": "Integrase Inhibitors"
                },
                {
                    "id": "D000004791",
                    "term": "Enzyme Inhibitors"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M25428",
                    "name": "Anti-Retroviral Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M333",
                    "name": "Raltegravir Potassium",
                    "asFound": "Green",
                    "relevance": "HIGH"
                },
                {
                    "id": "M21350",
                    "name": "Anti-HIV Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M4314",
                    "name": "Antiviral Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M4214",
                    "name": "Anti-Infective Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M21386",
                    "name": "Integrase Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M21385",
                    "name": "HIV Integrase Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M7951",
                    "name": "Enzyme Inhibitors",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "Infe",
                    "name": "Anti-Infective Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}